How does Sitagliptin interact with anti-inflammatory therapies in diabetes, and does it provide synergistic benefits for reducing chronic inflammation?
Sunil JoshiExplorer
Sign Up to our social questions and Answers Engine to ask questions, answer people’s questions, and connect with other people.
Please briefly explain why you feel this question should be reported.
Please briefly explain why you feel this answer should be reported.
Please briefly explain why you feel this user should be reported.
Sitagliptin, a DPP-4 inhibitor used in type 2 diabetes, does not have proven synergistic anti-inflammatory effects when combined with anti-inflammatory therapies.